Truist Financial Corp Has $754,000 Position in DaVita Inc. (NYSE:DVA)

Truist Financial Corp lessened its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 56.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,042 shares of the company's stock after selling 6,423 shares during the period. Truist Financial Corp's holdings in DaVita were worth $754,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Transcendent Capital Group LLC bought a new position in DaVita in the 3rd quarter worth approximately $25,000. Quarry LP bought a new position in DaVita during the third quarter worth $60,000. Versant Capital Management Inc raised its stake in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after purchasing an additional 169 shares during the last quarter. Blue Trust Inc. boosted its holdings in DaVita by 39.7% in the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after purchasing an additional 131 shares during the period. Finally, Wingate Wealth Advisors Inc. acquired a new stake in DaVita in the 4th quarter worth $82,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Price Performance

Shares of NYSE DVA traded down $0.08 during midday trading on Thursday, reaching $139.92. 359,215 shares of the company traded hands, compared to its average volume of 784,902. The stock's 50-day simple moving average is $160.19 and its 200-day simple moving average is $158.12. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60. The firm has a market cap of $11.19 billion, a PE ratio of 13.03, a PEG ratio of 1.07 and a beta of 0.99.

Remove Ads

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Barclays boosted their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.